Product line for the manufacture of biopharmaceuticals now includes sterile claim, gamma-irradiated and non-irradiated options
Three product options: non-gamma irradiated, gamma irradiated (25kGy – 45kGy) or sterile claim (10-6 SAL)
Watson-Marlow Fluid Technology Group (WMFTG) has expanded its puresu single-use range, providing a combination of components that are safe and easy-to-install.
Puresu is designed for the end-to-end manufacture of biopharmaceuticals and personalised medicines, such as gene therapies. The expanded range consists of three new product options: sterile claim, gamma-irradiated and non-irradiated.
WMFTG’s puresu assemblies help companies overcome the challenges of bioprocessing, providing controlled, efficient and reliable single-use assemblies that simplify validation processes.
Featuring open architecture design, by using the single-use components customers can quickly create a sterile fluid path that meets their specific bioprocessing needs.
Sterile puresu is an optimal solution for critical fluid path bioprocesses and customers who require contamination risk mitigation. Gamma-irradiated puresu is suitable for customers who manage microbial control through bioburden reduction, and non-irradiated puresu is for process development activities.
Jim Sanford, Senior Product Manager, commented: “Our puresu customised assemblies offer a unique range of benefits to customers with different bioprocessing needs. We work with the customer to deliver a final design that is tailored to their individual requirements and specific applications. These new assemblies reinforce WMFTG’s reputation as a leading supplier of reliable and sterile tubing products for use in biopharmaceutical manufacturing.”